3line W S, Yun S H, Chun H K, et al. Pulmonary resection for me- taslases from colorectal cancer: prognostic factors and survival[ J ]. Int J Colorectal Dis, 2007, 22 (6) : 699 -704.
4Nakajima J. Puhnonary metastasis: rationale fur local treatments and technique[ J ]. Gen Thurae Cardiuvase Surg, 2010, 58 (9) : 445 -451.
6Chen F, Hanaoka N, Sato K, et al. Prognostic factors of puhnona- ry metaslasectomy for coloreclal carcinonlas [ J ]. World J Surg, 2009, 33(3) :505 -511.
5Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solide tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [ J ]. J Natl Cancer Inst,2000 ,92 :205
6Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinationgs inpatients with previously untreated metastatic colorectal cancer[ J]. J Clin Oncol, 2004,22 : 23
7de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first - line treatment in advanced colorectal cancer [ J ]. J Clin Oncol,2000,18:2938
8Tournigand C, Andre T, Achille E et al. FOLFIRI followed FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study [ J ]. J Clin Oncol,2004,22 :229
9Hurwitz H, Fehrenbacher L, Novotny Wet al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [ J ]. N Engl J Med, 2004, 350:2335
10Giantonio B, Catalano P, Meropol Net al. High - dose Bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200[J]. J Clin Oncol,2005, 23 (suppl) : abstract 2
